Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 6.

Mugavero, M J; May, M; Ribaudo, H J; Gulick, R M; Riddler, S A; Haubrich, R; Napravnik, S; Abgrall, S; Phillips, A; Harris, R; Gill, M J; de Wolf, F; Hogg, R; Günthard, H F; Chêne, G; D'Arminio Monforte, A; Guest, J L; Smith, C; Murillas, J; Berenguer, J; Wyen, C; Domingo, P; Kitahata, M M; Sterne, J A C; Saag, M S (2011). Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. Journal of Acquired Immune Deficiency Syndromes, 58(3):253-260.

Wyen, C; Hendra, H; Siccardi, M; Platten, M; Jaeger, H; Harrer, T; Esser, S; Bogner, J R; Brockmeyer, N H; Bieniek, B; Rockstroh, J; Hoffmann, C; Stoehr, A; Michalik, C; Dlugay, V; Jetter, A; Knechten, H; Klinker, H; Skaletz-Rorowski, A; Fätkenheuer, G; Egan, D; Back, D J; Owen, A (2011). Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. Journal of Antimicrobial Chemotherapy, 66(9):2092-2098.

Jetter, A; Fätkenheuer, G; Frank, D; Klaassen, T; Seeringer, A; Doroshyenko, O; Kirchheiner, J; Hein, W; Schömig, E; Fuhr, U; Wyen, C (2010). Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? Antiviral Therapy, 15(7):975-983.

Tomalik-Scharte, D; Doroshyenko, O; Kirchheiner, J; Jetter, A; Lazar, A; Klaassen, T; Frank, D; Wyen, C; Fätkenheuer, G; Fuhr, U (2008). No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam. European Journal of Clinical Pharmacology, 64(10):1033-1035.

Wyen, C; Fuhr, U; Frank, D; Aarnoutse, R E; Klaassen, T; Lazar, A; Seeringer, A; Doroshyenko, O; Kirchheiner, J C; Abdulrazik, F; Schmeisser, N; Lehmann, C; Hein, W; Schömig, E; Burger, D M; Fätkenheuer, G; Jetter, A (2008). Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clinical Pharmacology and Therapeutics, 84(1):75-82.

Wyen, C; Hendra, H; Vogel, M; Hoffmann, C; Knechten, H; Brockmeyer, N H; Bogner, J R; Rockstroh, J; Esser, S; Jaeger, H; Harrer, T; Mauss, S; van Lunzen, J; Skoetz, N; Jetter, A; Groneuer, C; Fätkenheuer, G; Khoo, S H; Egan, D; Back, D J; Owen, A (2008). Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 61(4):914-918.

This list was generated on Sat May 25 03:18:03 2019 CEST.